17153-Myelodysplastic Syndrome-High Risk-580

Myelodysplastic Syndrome

Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

  • Details

ClinicalTrials.gov ID: NCT03268954
Diagnosis Type: High Risk
USOR Number: 17153

  • Address

2070 W Rudasill Rd, Suite 130
Tucson, AZ 85704
P: (520) 797-4468

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.